Applied Clinical Trials
Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.
Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.
Procedures are those medical activities directly related to the protocol that may range from a blood draw to something far more complex. Nonprocedures include an equally broad range of activities, such as study coordinator time, facility charges, patient reimbursement, and meals.
Overheads are indirect institutional costs allocated to individual departments and their programs. These indirect costs can include such illustrative items as costs of the institution's general management, building maintenance, general administration, and in some cases, general marketing efforts.
Here we report U.S. overhead rates. Few pharmaceutical companies are willing to pay overhead costs to office-based investigators. However, most clinical trial agreements with institutions include an overhead figure.
Clinical grant data in GrantPlan from companies conducting 76% of all clinical studies demonstrate that, in general, overheads at academic medical centers are slightly higher than at other institutions.
Instiutions vs Actual Agreements in U.S.-Based Overhead Figures
Particularly noteworthy though is the significant difference between the overhead rate reported by the institution, frequently used as the starting point in negotiations, and the actual amount accepted in the contract by the institution.—TTC (For more information, please contact help@ttc-llc.com.)
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.